These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 23903757)

  • 1. Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican‑3‑derived peptide.
    Tada Y; Yoshikawa T; Shimomura M; Sawada Y; Sakai M; Shirakawa H; Nobuoka D; Nakatsura T
    Int J Oncol; 2013 Oct; 43(4):1019-26. PubMed ID: 23903757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HLA-A2-restricted glypican-3 peptide-specific CTL clones induced by peptide vaccine show high avidity and antigen-specific killing activity against tumor cells.
    Yoshikawa T; Nakatsugawa M; Suzuki S; Shirakawa H; Nobuoka D; Sakemura N; Motomura Y; Tanaka Y; Hayashi S; Nakatsura T
    Cancer Sci; 2011 May; 102(5):918-25. PubMed ID: 21281401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival.
    Sawada Y; Yoshikawa T; Nobuoka D; Shirakawa H; Kuronuma T; Motomura Y; Mizuno S; Ishii H; Nakachi K; Konishi M; Nakagohri T; Takahashi S; Gotohda N; Takayama T; Yamao K; Uesaka K; Furuse J; Kinoshita T; Nakatsura T
    Clin Cancer Res; 2012 Jul; 18(13):3686-96. PubMed ID: 22577059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma.
    Komori H; Nakatsura T; Senju S; Yoshitake Y; Motomura Y; Ikuta Y; Fukuma D; Yokomine K; Harao M; Beppu T; Matsui M; Torigoe T; Sato N; Baba H; Nishimura Y
    Clin Cancer Res; 2006 May; 12(9):2689-97. PubMed ID: 16675560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptide vaccine as an adjuvant therapy for glypican-3-positive hepatocellular carcinoma induces peptide-specific CTLs and improves long prognosis.
    Taniguchi M; Mizuno S; Yoshikawa T; Fujinami N; Sugimoto M; Kobayashi S; Takahashi S; Konishi M; Gotohda N; Nakatsura T
    Cancer Sci; 2020 Aug; 111(8):2747-2759. PubMed ID: 32449239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasmodium parasite as an effective hepatocellular carcinoma antigen glypican-3 delivery vector.
    Liu Q; Yang Y; Tan X; Tao Z; Adah D; Yu S; Lu J; Zhao S; Qin L; Qin L; Chen X
    Oncotarget; 2017 Apr; 8(15):24785-24796. PubMed ID: 28445973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cancer peptide vaccine targeted glypican-3 antigen].
    Nakatsura T
    Nihon Rinsho; 2017 Feb; 75(2):257-262. PubMed ID: 30562861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice.
    Motomura Y; Ikuta Y; Kuronuma T; Komori H; Ito M; Tsuchihara M; Tsunoda Y; Shirakawa H; Baba H; Nishimura Y; Kinoshita T; Nakatsura T
    Int J Oncol; 2008 May; 32(5):985-90. PubMed ID: 18425324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice.
    Dargel C; Bassani-Sternberg M; Hasreiter J; Zani F; Bockmann JH; Thiele F; Bohne F; Wisskirchen K; Wilde S; Sprinzl MF; Schendel DJ; Krackhardt AM; Uckert W; Wohlleber D; Schiemann M; Stemmer K; Heikenwälder M; Busch DH; Richter G; Mann M; Protzer U
    Gastroenterology; 2015 Oct; 149(4):1042-52. PubMed ID: 26052074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of an H2-Kb or H2-Db restricted and glypican-3-derived cytotoxic T-lymphocyte epitope peptide.
    Iwama T; Horie K; Yoshikawa T; Nobuoka D; Shimomura M; Sawada Y; Nakatsura T
    Int J Oncol; 2013 Mar; 42(3):831-8. PubMed ID: 23354275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination with liposome-coupled glypican-3-derived epitope peptide stimulates cytotoxic T lymphocytes and inhibits GPC3-expressing tumor growth in mice.
    Iwama T; Uchida T; Sawada Y; Tsuchiya N; Sugai S; Fujinami N; Shimomura M; Yoshikawa T; Zhang R; Uemura Y; Nakatsura T
    Biochem Biophys Res Commun; 2016 Jan; 469(1):138-143. PubMed ID: 26616051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Usefulness of a novel oncofetal antigen, glypican-3, for diagnosis and immunotherapy of hepatocellular carcinoma].
    Nishimura Y; Nakatsura T; Senju S
    Nihon Rinsho Meneki Gakkai Kaishi; 2008 Oct; 31(5):383-91. PubMed ID: 18974622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of HLA-A2 restricted epitopes of glypican-3 and induction of CTL responses in HLA-A2 transgenic mice.
    Jin X; Liu X; Zhou Z; Ding Y; Wu Y; Qiu J; Shen C
    Cancer Immunol Immunother; 2022 Jul; 71(7):1569-1582. PubMed ID: 34724090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glypican-3 could be an effective target for immunotherapy combined with chemotherapy against ovarian clear cell carcinoma.
    Suzuki S; Yoshikawa T; Hirosawa T; Shibata K; Kikkawa F; Akatsuka Y; Nakatsura T
    Cancer Sci; 2011 Sep; 102(9):1622-9. PubMed ID: 21668581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes.
    Nobuoka D; Motomura Y; Shirakawa H; Yoshikawa T; Kuronuma T; Takahashi M; Nakachi K; Ishii H; Furuse J; Gotohda N; Takahashi S; Nakagohri T; Konishi M; Kinoshita T; Komori H; Baba H; Fujiwara T; Nakatsura T
    Int J Oncol; 2012 Jan; 40(1):63-70. PubMed ID: 21922136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of glypican-3-specific CTLs in chronic hepatitis and liver cirrhosis.
    Hayashi E; Motomura Y; Shirakawa H; Yoshikawa T; Oba N; Nishinakagawa S; Mizuguchi Y; Kojima T; Nomura K; Nakatsura T
    Oncol Rep; 2009 Jul; 22(1):149-54. PubMed ID: 19513517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes.
    Sawada Y; Yoshikawa T; Shimomura M; Iwama T; Endo I; Nakatsura T
    Int J Oncol; 2015 Jan; 46(1):28-36. PubMed ID: 25354479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptide vaccines for hepatocellular carcinoma.
    Nobuoka D; Yoshikawa T; Sawada Y; Fujiwara T; Nakatsura T
    Hum Vaccin Immunother; 2013 Jan; 9(1):210-2. PubMed ID: 23442593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction and preliminary screening of HLA-A*0201-restricted epitope peptides of human GPC3.
    Hu P; Wei Z; Li R; Wu D; Meng Z
    Int J Immunogenet; 2016 Jun; 43(3):166-70. PubMed ID: 27102087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GPC3 DNA vaccine elicits potent cellular antitumor immunity against HCC in mice.
    Li SQ; Lin J; Qi CY; Fu SJ; Xiao WK; Peng BG; Liang LJ
    Hepatogastroenterology; 2014; 61(130):278-84. PubMed ID: 24901124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.